Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting reading...
http://www.pbs.org/nbr/site/onair/transcripts/090216g/
Exactly. They must expect to have a need for the money in the forseeable future. For those with a long term time horizon, it reflects more good than bad, IMO.
Possibly a "sell the news" event?
News on GERN?...
or stem cells?...
I'm no expert, but I like GERN for several reasons.
Thay have a lot if Intellectual Property in the hESC arena. They have been involved from very early, and hold many fundamental patents.
They have a lot of irons in the fire, See their website: http://www.geron.com/products/ If any one of these approaches pans out, GERN will be a very profitable investment.
They have a large amount of cash on hand, about $175 million, and no debt. http://finance.yahoo.com/q/ks?s=GERN At their present burn rate, they are in good shape for a while. They are managing their finances very smartly.
The political climate has recently changed in Geron's favor, and more research monies and better FDA cooperation can only be good for GERN.
GERN is a very speculative investment, but one with a lot of potential, IMO.
Short interest in Geron has almost doubled from the middle to the end of January. Now more than 15 million shares from a total of only less than 80 million outstanding... A little good news and we'll be off to the races...
http://www.reuters.com/article/marketsNews/idINN1030812920090210?rpc=44
Below are the five Nasdaq stocks that experienced the largest increases and
decreases in their short positions from mid-January to late January, according
to information released by the exchange. The five companies with the largest overall short positions are also
listed. The latest date is as of Jan 30, while the previous period's data is as of
Jan 15.
COMPANY JAN 30 JAN 15 NET CHANGE PCT CHANGE
-----------------------------------------------------------------------------
FIVE BIGGEST INCREASES:
Sirius XM Radio (SIRI.O) 271,931,355 219,626,558 52,304,797 23.8
Geron Corp (GERN.O) 15,691,935 8,543,297 7,148,638 83.7
Bed Bath & Beyond (BBBY.O) 29,388,487 23,472,514 5,915,973 25.2
Flextronics (FLEX.O) 24,123,279 18,333,022 5,790,257 31.6
JDS Uniphase (JDSU.O) 12,907,667 7,782,856 5,124,811 65.9
Granted that we haven't gone up, but we're not making new lows every other day either. It seems like the message I'm getting is that we're consolidating like one would expect to happen at times during or at the end of a bear market. We just don't know yet whether its the end of the bear or whether there's lower lows to be seen...
We are actually above where we were in the middle of November, above the January lows, which are above the December lows, which are above the November lows on many indexes. It looks to me like we are consolidating, building what posssibly, hopefully is a base to rise from in the future. What do you mean when you say we have gone nowhere but down?
GERN...
http://online.wsj.com/article/SB123268485825709415.html?mod=yahoo_hs&ru=yahoo
In a watershed moment for one of the most contentious areas of science and American politics, the U.S. Food and Drug Administration cleared the way for the first-ever human trial of a medical treatment derived from embryonic stem cells.
Geron Corp., a Menlo Park, Calif., biotechnology company, is expected to announce Friday that it received a green light from the agency to mount a study of its stem-cell treatment for spinal cord injuries in up to 10 patients. The announcement caps more than a decade of advances in the company's labs and comes on the cusp of a widely expected shift in U.S. policy toward support of embryonic stem-cell research after years of official opposition.
"This is the dawn of a new era in medical therapeutics," said Thomas B. Okarma,
So what's your best WAG about the likely high for GERN over the next 52 weeks? Think it'll hit $25? ...$50? ...$75? Give me something to look forward to...
It's about time for a dividend on QID...
Hey ZZMan
Couldnt you just look at a chart of the Russsell 1000 to see a longer term chart of BGU? Wouldnt it be the same chart with a different scale?
deleted...
my mistake...
THANKS, gtober...
Your right, of course... There's plenty of time left, and he who laughs last laughs best... But I'm sure enjoying the game for the moment...
[OT] Sorry about that, Lee... Hehehehehe.......
Thanks for all the responses.
Here's a few links to possible sources.
http://www.britersystems.com/historical.htm
http://www.hquotes.com/
http://www.linnsoft.com/tour/prefs_historical.htm
http://www.grainmarketresearch.com/quick_delivery_special.cfm
I don't know much about any of them. I'll probably go back to using Qcollector with a Qcharts subscription like I was doing about 8 years ago. It'll cost a few bucks, but it works very well. I was just hoping and expecting that something better (cheaper) would be out there by now.
TREND1, I see daily, weekly and monthly data available for download, but no intraday... Am I missing something?
Does anybody know a source where I can download intraday (30 minute) historical data for QQQQ, QLD, and QID free in Excel format? TIA...
Does anybody know a source where I can download intraday (30 minute) historical data for QQQQ, QLD, and QID free in Excel format? TIA...
Peter Schiff(sp?) on CNBC now...
Even if it's a true indication of the open tomorrow, that would only put it back where it was yesterday...
Check it out... Higher highs and higher lows... When's the last time we saw that...
Hey, Canny...
You say that holding equal dollar amounts of QLD and QID makes for "a good hedge"? Can you explain that strategy? How is that better than owning nothing? What am I missing?
Dew, What is your opinion of Geron? They seem to have a lot of potential. Thanks in advance.
http://biz.yahoo.com/bw/081028/20081028005715.html?.v=1
Geron Scientists and Collaborators Demonstrate Activity of Pancreatic Islet-Like Cells Derived From Human Embryonic Stem Cells in Diabetes
Tuesday October 28, 7:30 am ET
Survival of Diabetic Mice Improved After Transplantation of hESC-Derived ILCs
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN - News) today announced the publication of data showing the successful engraftment of human embryonic stem cell (hESC)-derived pancreatic islet-like clusters (ILCs) in diabetic mice. After transplantation, the ILCs continued to express important pancreatic islet proteins, responded to high levels of glucose in the blood, and extended the survival of recipient animals.
ADVERTISEMENT
Pancreatic islet cells normally secrete insulin in response to high levels of glucose in the blood to maintain steady levels. Type 1 diabetes is an autoimmune disease in which the insulin secreting islet cells are destroyed. Administering insulin is life-saving but does not truly mimic the body’s natural response to blood glucose and can result in serious complications such as diabetic retinopathy, nephropathy and neuropathy.
“There is a clinical need for pancreatic islet cells for patients with type 1 diabetes. Transplantation of primary islets from cadaveric donors by the Edmonton Protocol has shown success in reducing the need for insulin administration, but cell availability is severely limited,” said Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer. “The in vivo characterization of hESC-derived islet-like clusters is an important milestone in developing a treatment for diabetes using our hESC-derived islet cells, GRNIC1.”
The research, conducted by Geron scientists and collaborators at the University of Alberta, has been published online in advance of print in Cell Proliferation.
The studies show that ILCs derived from hESCs express the pancreatic hormones insulin, glucagon and C-peptide, as well as prohormone convertase 1/3 and 2, enzymes normally expressed in mature islets. The data also demonstrate that when the ILCs are transplanted under the kidney capsule of streptozotocin-induced diabetic immuno-incompetent mice they are responsive to elevated levels of glucose. Human C-peptide, a byproduct of normal insulin production, was detected in the serum of mice transplanted with ILCs after oral administration of glucose, but not detected in the absence of glucose administration or in control mice transplanted with either human fibroblast cells or undifferentiated hESCs. Survival and health of mice receiving ILCs was significantly improved. Comparison of survival in the study showed that 78.6% of ILC-implanted mice were surviving beyond 50 days post-transplant, compared to only 23.8% of the recipients of human fibroblast cells and no recipients of undifferentiated hESCs. In addition, ILC grafts recovered at least 40 days after transplantation still expressed pancreatic markers as further evidence of continued functionality.
“These data importantly demonstrate that β-islet like cells obtained from hESCs will survive when transplanted into a diabetic animal and show some functionality of pancreatic islets,” said Jane S. Lebkowski, Ph.D., Geron’s senior vice president of regenerative medicine. “The next milestone in therapeutic development is to further improve the function of the hESC-derived ILCs and achieve normal glucose regulation in animal models of diabetes.”
The differentiation protocol does not require serum or feeder layer cells and therefore allows scalable production of hESC-derived islet-like cells, an important condition for therapeutic development.
Geron’s intellectual property portfolio for diabetes cell therapy includes U.S. Patent No. 7,326,572 granted earlier this year with claims covering the widely used method for producing endoderm cells from hESCs, a critical step in generating pancreatic islet cells from hESCs. The patent broadens the coverage for Geron’s islet protocol beyond the scope of U.S. Patent 7,033,831 issued to Geron in 2006, covering the production of insulin secreting cells from hESCs. Geron also has two U.K. patents covering similar production methods. Geron holds the exclusive right to develop and commercialize hESC-derived pancreatic islet cells for therapeutic applications under the fundamental hESC patents assigned to the Wisconsin Alumni Research Foundation.
About Geron
Geron is a biopharmaceutical company that is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The products are based on our core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.
You're speaking of ETFs, correct?
Unfortunately, I haven't yet found a way to make flipping ETFs as profitable as flipping mutual funds was..{:>))...
Can you flip mutual funds anywhere any more?
Can you explain what you mean by punative measures?
Some of the things I like are instant fills on market orders every time... limit and stop loss orders that fill at reasonable prices, sometimes at prices more advantageous to me than I would expect... the ability to place conditional or contingent orders... $8 for any kind of order...
I dealt with E-trade at one time to compare them... I'll take Fidelity any time...
Fidelity won't accept an order more than 30% away from last trade... as tuna would say... carp
Thanks. Just as I expected (and hoped).
FYI http://en.wikipedia.org/wiki/The_Postman_Always_Rings_Twice
http://www.telegraph.co.uk/finance/financetopics/financialcrisis/3224615/Markets-hold-breath-as-360bn-Lehman-swaps-unwind.html
Has this been talked about much today?
brightness,
I know of a few neighborhoods I have seen in my travels which have numerous "For Sale" signs, but the neighborhoods themselves still look prosperous. I have not seen anything remotely resembling a "ghost town".
Do you have a few addresses or specific neighborhoods that one could view through Google's Streetview to verify these virtually abandoned areas?
Thanks.
Bought 5000 shares more...